What is ImmunityBio, Inc.'s reportable segment — SG&A?

ImmunityBio, Inc. (IBRX) reported reportable segment — SG&A of $45.77M in Q1 2026.

How has ImmunityBio, Inc.'s reportable segment — SG&A changed year-over-year?

ImmunityBio, Inc.'s reportable segment — SG&A increased by 40.2% year-over-year, from $32.65M to $45.77M.

What is the long-term trend for ImmunityBio, Inc.'s reportable segment — SG&A?

Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — SG&A has grown at a 13.5% compound annual growth rate (CAGR), from $102.71M to $150M.

ImmunityBio, Inc. IBRX Reportable Segment — SG&A

Similar metrics at other companies

BIIBReportable Segment — SG&A

$608.4M+1.2%

BBIOReportable Segment — SG&A

$163.9M+54.1%

EXELReportable Segment — Selling, general, and administrative

$122.87M+1.7%

MEDPReportable Segment — SG&A

$47.92M-17.2%

QXOReportable Segment — SG&A

$457.8M+1,792%

RBAReportable Segment — SG&A

$214.2M+4.5%

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s reportable segment — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s reportable segment — SG&A?: ImmunityBio, Inc. (IBRX) reported reportable segment — SG&A of $45.77M in Q1 2026.
How has ImmunityBio, Inc.'s reportable segment — SG&A changed year-over-year?: ImmunityBio, Inc.'s reportable segment — SG&A increased by 40.2% year-over-year, from $32.65M to $45.77M.
What is the long-term trend for ImmunityBio, Inc.'s reportable segment — SG&A?: Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — SG&A has grown at a 13.5% compound annual growth rate (CAGR), from $102.71M to $150M.